Hepatic Drug Metabolism
Hepatic Drug Metabolism - Related Videos
01:14
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
0 Views •
2025
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
07:54
Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
0 Views •
Cited by 6 •
2011
A progressive colonization procedure is described to further assess its impact on the host hepatic metabolism. Colonization is monitored non invasively by evaluating the urinary excretion of microbial co-metabolites by NMR-based metabolic profiling while hepatic metabolism is assessed by High Resolution Magic Angle Spinning (HR MAS) NMR profiling of intact biopsy.
07:56
A Comprehensive Rat Model For Assessing Hepatic Transport Pathways Through Simultaneous Lymphatic And Blood Vascular Sampling
0 Views •
2026
This experimental protocol describes a hepatic lymph duct-cannulated rat model that enables direct and quantitative assessment of hepatic lymphatic and vascular drainage. The model allows simultaneous sampling of hepatic lymph and systemic blood to investigate hepatic transport, metabolism, and immune signaling, supporting studies of drug pharmacokinetics and liver-specific biology.
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
0 Views •
Cited by 28 •
2017
Here, optimized methods to generate in vivo and in vitro models of hepatic steatosis and to analyze the steatotic phenotypes and related physiological parameters are described.
06:50
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
0 Views •
Cited by 1 •
2025
Here, we establish a metabolic profiling platform integrating three-dimensional (3D) glioma spheroids and imaging-based normalization via extracellular flux analysis. This approach enables more accurate assessment of tumor metabolic responses to drug treatments and provides insights into potential mechanisms of resistance.
FAQs
Phase I reactions commonly modify a medicine through oxidation, reduction, or hydrolysis, while Phase II reactions attach polar groups through conjugation. These stages can influence whether a compound becomes more water-soluble and easier to excrete. Their effects are not limited to elimination, because metabolism may also change a medicine’s activity by activating or inactivating compounds.
Metabolism can generate metabolites with effects distinct from those of the original medicine. In some cases, transformation activates a prodrug, whereas in others it inactivates the therapeutic compound. This distinction matters clinically because the observed treatment effect, duration of activity, and potential toxicity may depend on both the administered medicine and the compounds formed during its transformation.
Variation in hepatic enzyme activity can help explain why patients receiving medicines do not always experience identical responses. Because metabolism influences activity, duration, and elimination, differences in these enzyme-mediated transformations may contribute to weaker effects, prolonged effects, or toxicity. Recognizing this variability supports more careful interpretation of treatment outcomes in clinical research and practice.
Knowledge of hepatic drug metabolism helps clinicians and researchers evaluate how quickly a medicine may be transformed and eliminated. That information supports dose selection and helps predict drug interactions, in which one medicine may alter the handling or effects of another. Metabolic considerations therefore connect enzyme activity with practical decisions about treatment use and monitoring.
Researchers can use metabolic information to relate enzyme-mediated transformation to a medicine’s duration, activity, elimination, and toxicity. They can also examine whether a compound is activated, inactivated, or converted into metabolites with distinct effects. This framework helps explain differences in treatment response and provides a basis for studying why the same therapy may produce different clinical outcomes.
Safety and effectiveness depend partly on what happens to a medicine after administration. Hepatic metabolism may shorten or extend its activity, support excretion, or create metabolites with different effects. Assessing these possibilities helps clinical researchers interpret therapeutic benefit alongside toxicity risk, while also accounting for enzyme-related differences among patients and potential interactions between medicines.